Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing next-generation therapies targeting metabolic disorders.

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...

With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Novo Nordisk launches weightloss drug Wegovy in India at competitive prices, facing patent battles and high demand.

Danish pharma giant Novo Nordisk on Tuesday launched its blockbuster weight loss drug Wegovy as a once-a-week injection in ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, ...

Wegovy is being made available in five dosing strengths with an easy-to-use pen device, which does away the use of syringes ...